Stock PMVP PMV PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News PMV Pharmaceuticals, Inc.

Equities

PMVP

US69353Y1038

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-10 EDT 		5-day change 1st Jan Change
2.04 USD -2.86% Intraday chart for PMV Pharmaceuticals, Inc. +2.51% -34.19%
05-09 PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-12 Jefferies Starts PMV Pharmaceuticals With Buy Rating, $5 Price Target MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
AQ
PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Jefferies Starts PMV Pharmaceuticals With Buy Rating, $5 Price Target
MT
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
AQ
PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors
CI
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
AQ
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer
CI
North American Morning Briefing : Stock Futures -2-
DJ
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
AQ
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
AQ
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
AQ
PMV Pharmaceuticals, Inc. Announces Workforce Reduction of Approximately 30%
CI
PMV Pharmaceuticals Names Michael Carulli as CFO; Phase 2 Trial of Tumor Treatment on Track
MT
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
AQ
PMV Pharmaceuticals, Inc. Announces Chief Financial Officer Changes
CI
PMV Pharmaceuticals, Inc. Announces Executive Changes
CI
Ladenburg Thalmann Initiates PMV Pharmaceuticals at Buy With $7 Price Target
MT
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from NASDAQ Biotechnology Index
CI
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PMVP Stock
  4. News PMV Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW